CERO Therapeutics Holdings, Inc. announced on January 6, 2025, that its board of directors has determined to effect a one-for-one hundred reverse stock split of the company’s common stock. This corporate action is scheduled to take effect at 12:01 a.m. Eastern Time on January 8, 2025.
Upon the effectiveness of the reverse stock split, every one hundred issued shares of common stock will be combined into one issued share. This will reduce the number of outstanding shares of common stock from approximately 10,321,839 shares to approximately 103,218 shares.
Proportional adjustments will be made to shares available under equity incentive plans, as well as the exercise price and number of shares issuable upon exercise or conversion of outstanding stock options and other equity securities. The company's common stock will begin trading on a split-adjusted basis on The Nasdaq Global Market as of the opening of trading on January 8, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.